Mallia co-founder Prof. Dr. Alexander Steinkasserer and Dr. Dmytro Royzman published a commentary in the journal BJD discussing new data from a study on sCD83 in autoimmune-mediated hair loss and alopecia areata.
Public source
Publisher name
Public post
Independent research, published in the 𝘉𝘳𝘪𝘵𝘪𝘴𝘩 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘰𝘧 𝘋𝘦𝘳𝘮𝘢𝘵𝘰𝘭𝘰𝘨𝘺, adds new insights into the role of sCD83 in hair disorders. New data fr…
Company
Mallia
Mallia develops cosmetic applications for hair growth and biopharmaceutical therapies for hair loss.
- Industry
- Biotechnology Research
- Location
- Erlangen, DE
- Company size
- 11–50 employees
About Mallia
Mallia Innovations GmbH is the holding company strategically driving the development and commercialization of cosmetic applications and biopharmaceutical therapies of the immune modulatory sCD83 protein, targeting hair growth, hair loss and other dermatological indications, including wound healing. Subsidiary Mallia Aesthetics GmbH focuses on the development of cosmetic products to stimulate hair growth. Subsidiary Mallia Therapeutics GmbH focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata, among other conditions.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Q32 Bio Inc.
Q32 Bio Inc. is advancing its lead product candidate, bempikibart, a targeted biologic therapy for patients with alopecia areata.
Research & Knowledge
Skin Angels
Skin Angels published a recent paper titled Glucagon-Like Peptide-1 Receptor Agonists and Related Incretin Therapies in Dermatology: Patient Selection and Shared Decision-Making in Clinics in Dermatology, 2026 August 9.
Research & Knowledge
National Alopecia Areata Foundation
National Alopecia Areata Foundation published the first U.S. expert consensus treatment recommendations for adults with severe alopecia areata in JAMA Dermatology.
Research & Knowledge
American Academy of Dermatology
American Academy of Dermatology published a brief report in JAAD evaluating the temporary increase in hair shedding induced by topical minoxidil for androgenetic alopecia (AGA) over eight months.
Research & Knowledge
LabSkin Creations